ABBAZABBA
6 년 전
The hits keep coming.
A little CAPD DD: https://www.unvmed.com/ & http://canna-powder.com/
"In September 2017, the Company entered into Agreements with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, located in Jerusalem, Israel, for production of powders from cannabinoid oil for the treatment of a variety of medical conditions. The Company, through its newly-organized Israeli subsidiary, Canna Powder Ltd, agreed to fund a study entitled Powder Formulation of Cannanoid Oil and Yissum granted the Company an option for an exclusive world-wide license (subject to a definitive License Agreement), to commercially exploit the production of Cannabis Powder Medical Products. The Company successfully completed an equity raise of in excess of $1 million to fund the Study and the development and production of its Cannabis Powder Medical Products. On April 30, 2018, the Company filed a Form 10 to become a reporting Company under the Exchange Act, which Form 10 became effective on June 29, 2018. On May 2, 2018, Canna Powder Ltd entered into the License Agreement and a separate Research Agreement with Yissum. As a result, the Company is again deemed to be an operating company under the rules of the SEC. On July 11, 2018, FINRA approved the application to change the Company's name to CannaPowder Inc. and its trading symbol to CAPD."
Werbe
6 년 전
The CEO of SMGY is also CEO of Canna Powder out of Israel. They just were given a definitive license agreement and a research agreement with Yissum Research Development Company, out of Hebrew University of Jerusalem.
Below is info on merger and Nevada SOS and OTCMarkets profile showing same CEO.
Share Structure and Market Cap as of 05/15/2018
Market Cap 544,862
Authorized Shares 500,000,000
Outstanding Shares 9,906,577
Restricted 9,868,881
Unrestricted 37,696
Float 37,696
IMO they will fix Float issue after merger, no reason 2 merge into shell IMO if not 4 financing.
On 9/7/17, the Company entered into a Feasibility Study and Option Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, located in Jerusalem, Israel, the Company, through its newly-organized Israeli subsidiary, Canna Powder Ltd, agreed to fund a study entitled Powder Formulations of Cannanoid Oil and Yissum agreed to grant the Company an option to receive an exclusive world-wide license (subject to a definitive License Agreement), to commercially exploit Yissum's interest in the results of the Study related to production of powders from cannabinoid oil for the treatment of a variety of medical conditions.
On 4/30/18, the Company filed a Form 10 to become a reporting Company under the Exchange Act and on 5/2/18, Canna Powder Ltd entered into the definitive License Agreement and a separate Research Agreement with Yissum. As a result of the above, the Company is again deemed to be an operating company under the rules of the SEC. The Company has pending before FINRA an application to change the Company's name to CannaPowder Inc.